Melinta Therapeutics nabs FDA nod for more convenient rework of antibiotic Orbactiv, a former Eli Lilly candidate
As pressure rises to address the superbug crisis, Melinta Therapeutics says it now has a more convenient option to treat those with antibiotic-resistant skin infections.
Melinta got the OK for a new-and-improved formulation of its antibiotic oritavancin in acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of Gram-positive microorganisms, including MRSA, the company announced on Monday. The drug, marketed as Kimyrsa, can be administered over one hour as opposed to Melinta’s earlier Orbactiv, which takes three.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.